101 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.
Queen Mary University of London
Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.
National Institute of Biological Sciences
DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.
Glaxosmithkline
Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis.
Glaxosmithkline
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Ambit Biosciences
LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Eli Lilly and Company
Azaindole derivatives as potential kinase inhibitors and their SARs elucidation.
Hunan University of Science and Technology
Exploring positions 6 and 7 of a quinazoline-based scaffold leads to changes in selectivity and potency towards RIPK2/3 kinases.
Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
Identification of Pyrido[3,4-d]pyrimidine derivatives as RIPK3-Mediated necroptosis inhibitors.
Korea University
Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
Soochow University
Preclinical Evaluation of Dihydropyrazole-Cored Positron Emission Tomography (PET) Ligands for Imaging of Receptor-Interacting Serine/Threonine Protein Kinase 1 (RIPK1) in the Brain.
Beijing Normal University
Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors.
Ningxia Medical University
From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.
Sichuan University
Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.
West China Hospital of Sichuan University
RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development.
Lanzhou University Second Hospital
Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy.
Ningxia Medical University
Discovery of Sibiriline derivatives as novel receptor-interacting protein kinase 1 inhibitors.
China Pharmaceutical University
Targeting Receptor-Interacting Protein Kinase 1 by Novel Benzothiazole Derivatives: Treatment of Acute Lung Injury through the Necroptosis Pathway.
Ningxia Medical University
Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity.
Zhejiang University
The Hitchhiker's Guide to Deep Learning Driven Generative Chemistry.
Insilico Medicine Hong Kong
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
Smith, Gambrell & Russell
From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors.
The Walter and Eliza Hall Institute of Medical Research
Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer's Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis.
Smith, Gambrell & Russell
Scaffold hopping derived novel benzoxazepinone RIPK1 inhibitors as anti-necroptosis agents.
Ningxia Medical University
Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.
Ningxia Medical University
Design, synthesis, and structure-activity relationship of novel RIPK2 inhibitors.
Soochow University
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
West China Hospital
Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors.
Ningxia Medical University
Discovery of novel 2,8-diazaspiro[4.5]decan-1-one derivatives as potent RIPK1 kinase inhibitors.
China Pharmaceutical University
Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs).
West China Hospital
Discovery of a Trifluoromethoxy Cyclopentanone Benzothiazole Receptor-Interacting Protein Kinase 1 Inhibitor as the Treatment for Alzheimer's Disease.
China Pharmaceutical University
Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Soochow University
Novel RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.
Smith, Gambrell & Russell
Enantiomeric profiling of a chiral benzothiazole necroptosis inhibitor.
Ningxia Medical University
Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1.
Paris-Saclay University
Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.
Genentech
-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[
Ningxia Medical University
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
Fudan University
Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.
Glaxosmithkline
Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage.
Bristol-Myers Squibb Research & Development
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.
Glaxosmithkline
Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Sichuan University/Collaborative Innovation Center of Biotherapy
Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships.
Takeda Pharmaceutical
PIPERIDINYL-METHYLPURINE PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS
K36 Therapeutics
PYRAZOLE MEMBRANE-ASSOCIATED TYROSINE-AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE (PKMYT1) INHIBITORS AND USES THEREOF
Insilico Medicine Ip
COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES
Veralox Therapeutics
SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Shanghai Annova Biotechnology
COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF
Gluetacs Therapeutics (Shanghai) Co.
Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs
Intra-Cellular Therapies
COMPOSITION FOR PREVENTING OR TREATING GRAVES' DISEASE COMPRISING COMPOUND CONTAINING AN IMIDAZOPYRIDINE STRUCTURE AS ACTIVE INGREDIENT
Esgelbio
PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT
Korea Reserarch Institute of Chemical Technology
NAMPT ACTIVATORS FOR TREATING METABOLIC AND NEUROLOGICAL DISORDERS
University of Illinois
NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES
Enliven
Benzothiophene-based selective estrogen receptor downregulator compounds
University of Illinois
Pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and preparation method therefor and application thereof
Suzhou Genhouse Pharmaceutical Co.
5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof
Biosplice Therapeutics
Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
The Institute of Cancer Research: Royal Cancer Hospital
Phosphonate linkers and their use to facilitate cellular retention of compounds
Merck Sharp & Dohme
Small molecule activators of Parkin enzyme function
Mayo Foundation For Medical Education and Research
Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof
La Jolla Institute of Allergy & Immunology
Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof
Beijing Innocare Pharma Tech
Piperazinyl norbenzomorphan compounds and methods for using the same
University Of Texas
Alpha-truxillic acid derivatives and pharmaceutical compositions thereof
The State University of New York
HDAC inhibitor compounds and methods of treatment
University of Florida Research Foundation
5-aromatic alkynyl substituted benzamide compound and preparation method, pharmaceutical composition, and use thereof
Shanghai Institute of Material Medica, Chinese Academy of Sciences
Inhibitors of cellular necrosis and related methods
President and Fellows of Harvard College
2-amino 6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
Pfizer
Evaluation of in vitro effects of some analgesic drugs on erythrocyte and recombinant carbonic anhydrase I and II.
Balikesir University
Methods of treatment of histamine H-4 receptor-related pruritus associated with nerve disorders
Bridge Pharma
Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof
Sanofi